Loading…

Abstract 547: Role of KDM4A in bladder cancer

Bladder cancer (BCa) is the most common malignancy of the urinary system in the United States. Most patients present with non-muscle invasive bladder cancer (NMIBC) that is treated with bladder preserving approaches. However, recurrence is high with a 50% chance to progression into muscle invasive b...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2023-04, Vol.83 (7_Supplement), p.547-547
Main Authors: Warren, Bailey O., Abdelfattah, Ammar Y., Ghoneum, Alia, Salsbury, Freddie, Said, Neveen A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 547
container_issue 7_Supplement
container_start_page 547
container_title Cancer research (Chicago, Ill.)
container_volume 83
creator Warren, Bailey O.
Abdelfattah, Ammar Y.
Ghoneum, Alia
Salsbury, Freddie
Said, Neveen A.
description Bladder cancer (BCa) is the most common malignancy of the urinary system in the United States. Most patients present with non-muscle invasive bladder cancer (NMIBC) that is treated with bladder preserving approaches. However, recurrence is high with a 50% chance to progression into muscle invasive bladder cancer (MIBC). Patients with MI disease are treated with aggressive surgery and/or systemic chemo-radiation, and more recently immune- and targeted therapies. Patients with BCa require life-long surveillance with expensive imaging, and repeated treatment courses, making BCa one of the most expensive malignancies throughout the patients’ lifespan. BCa therapies have been stagnant for almost four decades until 2016 when new immune and targeted therapies were approved for patients with locally advanced, recurrent, or metastatic disease, with an overall response of 15-29%. Thus, better understanding of the pathobiology of BCa is needed to identify actionable targets and develop novel therapeutics. In this respect, we have identified histone lysine demethylase 4A (KDM4A), also known as Jumanji D2A (JMJD2A) as a BCa onco-protein. We found that the expression of nuclear KDM4A significantly correlated with disease stage in patients’ tumors and in tobacco carcinogen-induced murine bladder tumors. KDM4A transcript expression significantly increased in bladder tumors compared to normal in TCGA data and three independent publicly available datasets. Knockdown of KDM4A in BCa cell lines significantly inhibited their proliferation and invasiveness. Interestingly, KDM4A transcripts exhibited significant inverse correlation with BCa tumor suppressor SPARC in five independent datasets. In addition, using phenotypic screening and computational modeling, we found that KDM4A is a direct target of verteporfin, a potent inducer of SPARC expression in BCa cell lines. Mechanistically, knockdown of KDM4A in BCa cell lines increased SPARC expression, whereas its overexpression inhibited basal and verteporfin-induced SPARC expression. Chromatin immune-precipitation (ChIP) assays indicated that verteporfin significantly inhibited the association of KDM4A with SPARC promoter. Together, our data underscore the oncogenic role of KDM4A in BCa and its potential as an actionable target. Citation Format: Bailey O. Warren, Ammar Y. Abdelfattah, Alia Ghoneum, Freddie Salsbury, Neveen A. Said. Role of KDM4A in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer R
doi_str_mv 10.1158/1538-7445.AM2023-547
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_AM2023_547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_AM2023_547</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1158_1538_7445_AM2023_5473</originalsourceid><addsrcrecordid>eNpjYJAxNNAzNDS10Dc0NbbQNTcxMdVz9DUyMDLWNTUxZ2LghAuzILE5GLiKi7MMDAxMDQ1MORl0HZOKS4oSk0sUgHqsFILyc1IV8tMUvF18TRwVMvMUknISU1JSixSSE_OSU4t4GFjTEnOKU3mhNDeDiZtriLOHbnJRfnFxUWpafEFRZm5iUWW8oUE8yGnxIHvjQfbGQ5wWD7TGmExtAJgxPxk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 547: Role of KDM4A in bladder cancer</title><source>EZB Electronic Journals Library</source><creator>Warren, Bailey O. ; Abdelfattah, Ammar Y. ; Ghoneum, Alia ; Salsbury, Freddie ; Said, Neveen A.</creator><creatorcontrib>Warren, Bailey O. ; Abdelfattah, Ammar Y. ; Ghoneum, Alia ; Salsbury, Freddie ; Said, Neveen A.</creatorcontrib><description>Bladder cancer (BCa) is the most common malignancy of the urinary system in the United States. Most patients present with non-muscle invasive bladder cancer (NMIBC) that is treated with bladder preserving approaches. However, recurrence is high with a 50% chance to progression into muscle invasive bladder cancer (MIBC). Patients with MI disease are treated with aggressive surgery and/or systemic chemo-radiation, and more recently immune- and targeted therapies. Patients with BCa require life-long surveillance with expensive imaging, and repeated treatment courses, making BCa one of the most expensive malignancies throughout the patients’ lifespan. BCa therapies have been stagnant for almost four decades until 2016 when new immune and targeted therapies were approved for patients with locally advanced, recurrent, or metastatic disease, with an overall response of 15-29%. Thus, better understanding of the pathobiology of BCa is needed to identify actionable targets and develop novel therapeutics. In this respect, we have identified histone lysine demethylase 4A (KDM4A), also known as Jumanji D2A (JMJD2A) as a BCa onco-protein. We found that the expression of nuclear KDM4A significantly correlated with disease stage in patients’ tumors and in tobacco carcinogen-induced murine bladder tumors. KDM4A transcript expression significantly increased in bladder tumors compared to normal in TCGA data and three independent publicly available datasets. Knockdown of KDM4A in BCa cell lines significantly inhibited their proliferation and invasiveness. Interestingly, KDM4A transcripts exhibited significant inverse correlation with BCa tumor suppressor SPARC in five independent datasets. In addition, using phenotypic screening and computational modeling, we found that KDM4A is a direct target of verteporfin, a potent inducer of SPARC expression in BCa cell lines. Mechanistically, knockdown of KDM4A in BCa cell lines increased SPARC expression, whereas its overexpression inhibited basal and verteporfin-induced SPARC expression. Chromatin immune-precipitation (ChIP) assays indicated that verteporfin significantly inhibited the association of KDM4A with SPARC promoter. Together, our data underscore the oncogenic role of KDM4A in BCa and its potential as an actionable target. Citation Format: Bailey O. Warren, Ammar Y. Abdelfattah, Alia Ghoneum, Freddie Salsbury, Neveen A. Said. Role of KDM4A in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 547.</description><identifier>ISSN: 1538-7445</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2023-547</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.547-547</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Warren, Bailey O.</creatorcontrib><creatorcontrib>Abdelfattah, Ammar Y.</creatorcontrib><creatorcontrib>Ghoneum, Alia</creatorcontrib><creatorcontrib>Salsbury, Freddie</creatorcontrib><creatorcontrib>Said, Neveen A.</creatorcontrib><title>Abstract 547: Role of KDM4A in bladder cancer</title><title>Cancer research (Chicago, Ill.)</title><description>Bladder cancer (BCa) is the most common malignancy of the urinary system in the United States. Most patients present with non-muscle invasive bladder cancer (NMIBC) that is treated with bladder preserving approaches. However, recurrence is high with a 50% chance to progression into muscle invasive bladder cancer (MIBC). Patients with MI disease are treated with aggressive surgery and/or systemic chemo-radiation, and more recently immune- and targeted therapies. Patients with BCa require life-long surveillance with expensive imaging, and repeated treatment courses, making BCa one of the most expensive malignancies throughout the patients’ lifespan. BCa therapies have been stagnant for almost four decades until 2016 when new immune and targeted therapies were approved for patients with locally advanced, recurrent, or metastatic disease, with an overall response of 15-29%. Thus, better understanding of the pathobiology of BCa is needed to identify actionable targets and develop novel therapeutics. In this respect, we have identified histone lysine demethylase 4A (KDM4A), also known as Jumanji D2A (JMJD2A) as a BCa onco-protein. We found that the expression of nuclear KDM4A significantly correlated with disease stage in patients’ tumors and in tobacco carcinogen-induced murine bladder tumors. KDM4A transcript expression significantly increased in bladder tumors compared to normal in TCGA data and three independent publicly available datasets. Knockdown of KDM4A in BCa cell lines significantly inhibited their proliferation and invasiveness. Interestingly, KDM4A transcripts exhibited significant inverse correlation with BCa tumor suppressor SPARC in five independent datasets. In addition, using phenotypic screening and computational modeling, we found that KDM4A is a direct target of verteporfin, a potent inducer of SPARC expression in BCa cell lines. Mechanistically, knockdown of KDM4A in BCa cell lines increased SPARC expression, whereas its overexpression inhibited basal and verteporfin-induced SPARC expression. Chromatin immune-precipitation (ChIP) assays indicated that verteporfin significantly inhibited the association of KDM4A with SPARC promoter. Together, our data underscore the oncogenic role of KDM4A in BCa and its potential as an actionable target. Citation Format: Bailey O. Warren, Ammar Y. Abdelfattah, Alia Ghoneum, Freddie Salsbury, Neveen A. Said. Role of KDM4A in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 547.</description><issn>1538-7445</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpjYJAxNNAzNDS10Dc0NbbQNTcxMdVz9DUyMDLWNTUxZ2LghAuzILE5GLiKi7MMDAxMDQ1MORl0HZOKS4oSk0sUgHqsFILyc1IV8tMUvF18TRwVMvMUknISU1JSixSSE_OSU4t4GFjTEnOKU3mhNDeDiZtriLOHbnJRfnFxUWpafEFRZm5iUWW8oUE8yGnxIHvjQfbGQ5wWD7TGmExtAJgxPxk</recordid><startdate>20230404</startdate><enddate>20230404</enddate><creator>Warren, Bailey O.</creator><creator>Abdelfattah, Ammar Y.</creator><creator>Ghoneum, Alia</creator><creator>Salsbury, Freddie</creator><creator>Said, Neveen A.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230404</creationdate><title>Abstract 547: Role of KDM4A in bladder cancer</title><author>Warren, Bailey O. ; Abdelfattah, Ammar Y. ; Ghoneum, Alia ; Salsbury, Freddie ; Said, Neveen A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1158_1538_7445_AM2023_5473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warren, Bailey O.</creatorcontrib><creatorcontrib>Abdelfattah, Ammar Y.</creatorcontrib><creatorcontrib>Ghoneum, Alia</creatorcontrib><creatorcontrib>Salsbury, Freddie</creatorcontrib><creatorcontrib>Said, Neveen A.</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warren, Bailey O.</au><au>Abdelfattah, Ammar Y.</au><au>Ghoneum, Alia</au><au>Salsbury, Freddie</au><au>Said, Neveen A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 547: Role of KDM4A in bladder cancer</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2023-04-04</date><risdate>2023</risdate><volume>83</volume><issue>7_Supplement</issue><spage>547</spage><epage>547</epage><pages>547-547</pages><issn>1538-7445</issn><eissn>1538-7445</eissn><abstract>Bladder cancer (BCa) is the most common malignancy of the urinary system in the United States. Most patients present with non-muscle invasive bladder cancer (NMIBC) that is treated with bladder preserving approaches. However, recurrence is high with a 50% chance to progression into muscle invasive bladder cancer (MIBC). Patients with MI disease are treated with aggressive surgery and/or systemic chemo-radiation, and more recently immune- and targeted therapies. Patients with BCa require life-long surveillance with expensive imaging, and repeated treatment courses, making BCa one of the most expensive malignancies throughout the patients’ lifespan. BCa therapies have been stagnant for almost four decades until 2016 when new immune and targeted therapies were approved for patients with locally advanced, recurrent, or metastatic disease, with an overall response of 15-29%. Thus, better understanding of the pathobiology of BCa is needed to identify actionable targets and develop novel therapeutics. In this respect, we have identified histone lysine demethylase 4A (KDM4A), also known as Jumanji D2A (JMJD2A) as a BCa onco-protein. We found that the expression of nuclear KDM4A significantly correlated with disease stage in patients’ tumors and in tobacco carcinogen-induced murine bladder tumors. KDM4A transcript expression significantly increased in bladder tumors compared to normal in TCGA data and three independent publicly available datasets. Knockdown of KDM4A in BCa cell lines significantly inhibited their proliferation and invasiveness. Interestingly, KDM4A transcripts exhibited significant inverse correlation with BCa tumor suppressor SPARC in five independent datasets. In addition, using phenotypic screening and computational modeling, we found that KDM4A is a direct target of verteporfin, a potent inducer of SPARC expression in BCa cell lines. Mechanistically, knockdown of KDM4A in BCa cell lines increased SPARC expression, whereas its overexpression inhibited basal and verteporfin-induced SPARC expression. Chromatin immune-precipitation (ChIP) assays indicated that verteporfin significantly inhibited the association of KDM4A with SPARC promoter. Together, our data underscore the oncogenic role of KDM4A in BCa and its potential as an actionable target. Citation Format: Bailey O. Warren, Ammar Y. Abdelfattah, Alia Ghoneum, Freddie Salsbury, Neveen A. Said. Role of KDM4A in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 547.</abstract><doi>10.1158/1538-7445.AM2023-547</doi></addata></record>
fulltext fulltext
identifier ISSN: 1538-7445
ispartof Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.547-547
issn 1538-7445
1538-7445
language eng
recordid cdi_crossref_primary_10_1158_1538_7445_AM2023_547
source EZB Electronic Journals Library
title Abstract 547: Role of KDM4A in bladder cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A50%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%20547:%20Role%20of%20KDM4A%20in%20bladder%20cancer&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Warren,%20Bailey%20O.&rft.date=2023-04-04&rft.volume=83&rft.issue=7_Supplement&rft.spage=547&rft.epage=547&rft.pages=547-547&rft.issn=1538-7445&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2023-547&rft_dat=%3Ccrossref%3E10_1158_1538_7445_AM2023_547%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-crossref_primary_10_1158_1538_7445_AM2023_5473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true